Share on facebook
Share on twitter
Share on linkedin
Share on email

Media: Financial Times

Vaxxinity hopes its Covid jab technology will help treat Alzheimer’s

Covid-19 has already resulted in the first approved mRNA-based vaccines and now Vaxxinity is developing a new coronavirus vaccine using synthetic proteins that it says may have wide application.

“Some of the most successful drugs today are biologics, but they are very expensive and often quite inconvenient to use. Our vision is to interrupt that class of drugs with next-generation and next-level vaccines, ”Mei Mei Hu, executive director of Vaxxinity, told the Financial Times.